Author: Jessica Wapner ISBN : Product Detai New from Format: PDFOne of Publishers Weekly’s Top Ten Spring 2013 Science Books
Philadelphia, 1959: A scientist scrutinizing a single human cell under a microscope detects a missing piece of DNA. That scientist, David Hungerford, had no way of knowing that he had stumbled upon the starting point of modern cancer research—the Philadelphia chromosome. This book charts not only that landmark discovery, but also—for the first time, all in one place—the full sequence of scientific and medical discoveries that brought about the first-ever successful treatment of a lethal cancer at the genetic level.
The significance of this mutant chromosome would take more than three decades to unravel; in 1990, it was recognized as the sole cause of a deadly blood cancer, chronic myeloid leukemia, or CML. This dramatic discovery launched a race involving doctors and researchers around the world, who recognized that in principle it might be possible to target CML at its genetic source.
Science journalist Jessica Wapner brings extensive original reporting to this book, including interviews with more than thirty-five people with a direct role in this story. Wapner reconstructs more than forty years of crucial breakthroughs, clearly explains the science behind them, and pays tribute to the dozens of researchers, doctors, and patients whose curiosity and determination restored the promise of a future to the more than 70,000 people worldwide who are diagnosed with CML each year. Chief among them is researcher and oncologist Dr. Brian Druker, whose dedication to his patients fueled his quest to do everything within his power to save them.
The Philadelphia Chromosome helps us to fully understand and appreciate just how pathbreaking, hard-won, and consequential are the achievements it recounts—and to understand the principles behind much of today’s most important cancer research, as doctors and scientists race to uncover and treat the genetic roots of a wide range of cancers.
- File Size: 1453 KB
- Print Length: 320 pages
- Publisher: The Experiment; 1 edition (May 10, 2013)
- Sold by: Amazon Digital Services, Inc.
- Language: English
- ASIN: B00BBF8FL4
- Text-to-Speech: Enabled
- Lending: Enabled
- Amazon Best Sellers Rank: #170,260 Paid in Kindle Store (See Top 100 Paid in Kindle Store)
- #6 in Books > Health, Fitness & Dieting > Diseases & Physical Ailments > Cancer > Leukemia
- #36 in Kindle Store > Kindle eBooks > Nonfiction > Professional & Technical > Professional Science > Chemistry > General & Reference
- #36 in Kindle Store > Kindle eBooks > Nonfiction > Science > Chemistry > General & Reference
- #6 in Books > Health, Fitness & Dieting > Diseases & Physical Ailments > Cancer > Leukemia
- #36 in Kindle Store > Kindle eBooks > Nonfiction > Professional & Technical > Professional Science > Chemistry > General & Reference
- #36 in Kindle Store > Kindle eBooks > Nonfiction > Science > Chemistry > General & Reference
The Philadelphia Chromosome: A Mutant Gene and the Quest to Cure Cancer at the Genetic Level PDF
Reading the Philadelphia Chromosome transformed me into a mini scientist majoring in CML, Chronic Myelogenous Leukemia. I was diagnosed with CML in November of 2003, which required keeping up-to-date on news relating to CML. When I heard about the Philadelphia Chromosome by Jessica Wapner, I was anxious to add it to my shelf of resources.
Reading the book with pencil in hand to highlight new facts as well as valuable previous knowledge, I found myself marking information on every page.
When I was diagnosed my oncologist informed me that if there was ever a good time to get CML, it was now. At that precise moment, I had no idea what he was talking about. He may have elaborated, but in that moment of shock, I didn't hear much. Wapner's book has renewed my appreciation of that conversation every time I swallow my oral chemotherapy pill, Gleevec.
I have an entire file cabinet filled with lab results since 2003. My oncologist reviews the findings with me twice a year, but after reading the Philadelphia Chromosome, my understanding of the labs has improved. I have registered for a couple of CML conferences and am confident I will easily grasp new information presented after reading this book.
Years ago I started writing a book about living with CML. I found it too depressing to continue, however, not abandoning the therapeutic effect; I turned it into a blog, which I update once a month. marycrocco.wordpress.com Being helpful to a few readers who have stopped by makes it worthwhile.
Wapner shared a story of a patient who cherished her Gleevec and defended it with her life. I do the same thing, always insisting to sign for it and checking the delivery time is set for the morning.
This book is divided into roughly three parts. The first part consists of an account of how scientists tracked a certain kind of leukemia down to its genetic origins. Some of the explanation here can be a little difficult. But don't be put off. While this section doesn't necessarily make for light bedtime reading - it is accessible. Wapner presents the material in short, easily digestible chapters. She frequently reviews what's been covered so far, and she is a master of writing clear, logical sentences that include analogies from everyday life. So you will readily enough be able to understand this section if you just turn off the TV and concentrate for short stretches.
Your diligence will be rewarded. At the end of this section, you'll have a clear understanding of how this type of cancer, and of how cancers in general, can arise in the very core of our cells. You'll also understand how a drug can be tailored to specifically stymie the action of the aberrant chromosomes.
The second section deals with how Brian Druker and others ushered such a drug through the necessary test phases. Reading about this often frustrating process, you'll learn how tests must progress from animal to human subjects in order to eventually try for FDA approval. The pill that was eventually formulated proved to be so much more successful at fighting back the cancer than previous drugs or procedures, it was fast-tracked for FDA approval. Here the reading gets easier, although perhaps not quite as interesting.
Finally, Wapner recounts how the drug was named Gleevec and was marketed. She also tells how this pioneering drug has opened the door to what's become a flood of other drugs targeted at blocking the chemical chain of events that arise from a mutated gene.
No comments:
Post a Comment